Statistics from Altmetric.com
Xie L, Xu J, Sun X, et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer 2020;8:e000798. doi: 10.1136/jitc-2020-000798.
Since the online publication of this article, the authors have noticed that in figure 4 the dotted and full lines were mislabelled. Please see the corrected Figure below:
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.